Chandra Wilson of Grey’s Anatomy Honored By Associates For Breast And Prostate Cancer Studies

Chandra Wilson of Grey’s Anatomy Honored By Associates For Breast And Prostate Cancer Studies

May 6, 2015 The Associates For Breast and Prostate Cancer Studies, affectionately known as the ABCs, hosted its annual, star-studded Mother’s Day Luncheon at the Four Seasons Hotel at Beverly Hills, Wednesday, May 6, 2015 to benefit breast and prostate cancer research at John Wayne Cancer Institute at Providence Saint John’s Health Center.

The event honored award-winning actress, writer and director Chandra Wilson, star of Grey’s Anatomy, and author and former top model Brandi Glanville of The Real Housewives of Beverly Hills with the organization’s “Women of Achievement Award.”

Beverly Cohen and Sheri Rosenblum co-chaired the event which featured an informal fashion show by St. John Boutique. Actress, comedienne and author Lisa Ann Walter, was the emcee.

The ABCs was formed 25 years ago by a group of dedicated philanthropists who had originally been associated with the Eddie Cantor Charitable Foundation. These individuals wanted to devote all their charitable efforts and resources to eradicating cancer and unanimously chose to support progressive and innovative breast cancer and prostate cancer research at the John Wayne Cancer Institute. Since 1990, the ABCs have raised over $14 million. For more information, please

Since 1981, the family of John Wayne has been committed to pioneering cancer research in memory of their father, who died of cancer. For more than 30 years, the courageous and dedicated researchers at the John Wayne Cancer Institute have made groundbreaking discoveries that have changed the way cancer is detected, diagnosed and treated around the world. Today the tradition of excellence continues as the Institute spearheads new research advances, while training the next generation of leaders in the fight against cancer through its renowned Surgical Oncology Fellowship Program. The Institute’s programs focus on melanoma, breast, neuro, prostate and gastrointestinal cancers, as well as innovative research in cancer genomics, molecular biomarkers, and chemo- and immunotherapies. With its unique ability to rapidly turn scientific discoveries into novel approaches for early detection and treatment, the Institute provides immediate hope to cancer patients everywhere. For more information, please visit